


FIGURE 1







FIG. 3a









FIG. 3C




FIG. 3d





FIG. 3e






Fig. 4

10




FIG. 5a




FIG. 5b




FIG. 5c




FIG. 5d




FIG. 5e

PATIENT CHARACTERISTICS	CLINICAL RESPONSE		
	Complete Response	Partial Response	Overall Response
Demographics			
Age			
Pathology			
Tumor Size			
Histology (1)			
Estrogen Receptor Status (2)			
Site of Metastasis			
Clinical Status			
Disease Stage (3)			
Menopausal Status (4)			
Prior Treatment Status			
Surgical (5)			
Chemotherapy (6)			
Radiotherapy			
Treatment Status			
Complications/Toxicity (7)			
Performance Status (8)			
Time to Progression/Treatment Failure			
(1) Infiltrating ductal, lobular (small-cell), medullary, tubular, squamous cell, adenocarcinoma, angiosarcoma			
(2) Positive or negative estrogen receptor			
(3) TNM staging criteria			
(4) Pre- or postmenopausal			
(5) Radical mastectomy, modified radical mastectomy, limited excision (lumpectomy)			
(6) CMF (cyclophosphamide, methotrexate, 5-fluorouracil), CA (cyclophosphamide and doxorubicin), tamoxifen			
(7) NCI common toxicity scale-Hematopoietic (leukopenia, neutropenia, anemia, thrombocytopenia), infectious (fever, localized infection, sepsis), neurological, endocrine (hyper- or hypoglycemia), cardiac (CHF), constitutional (nausea, vomiting, malnutrition, stomatitis, lethargy, malaise)			
(8) Karnofsky			

Fig. 6a

RESPONSE

PATIENT CHARACTERISTICS	Clinical	Complete	Partial	Overall	Work Participation
		Resource Use	QOL	QALYS	
Demographics					
Age					
Pathology					
Tumor Size					
Histology (1)					
Estrogen Receptor Status (2)					
Site of Metastasis					
Risk/Prognostic Factors					
Familial					
Genetic Susceptibility					
APC					
AR					
AT					
BCL1					
BCL2					
BRCA1					
BRCA2					
CTSD					
EGF					
EGFR					
HRAS					
IGFIR					
LMYC					
NM23					
p53					
SRC					
Prior History					
In situ					
Invasive					
Atypical Hyperplasia					
Endogenous Endocrine Factors					
Age at Menarche					
Age at Menopause					
Age at First Pregnancy					
Exogenous Endocrine Factors					
Hormone Replacement Therapy					
Oral Contraceptives					
Environmental Factors					
Clinical Status					
Disease Stage (3)					
Menopausal Status (4)					
Prior Treatment Status					
Surgical (5)					
Chemotherapy (6)					
Radiotherapy					
Treatment Status					
Complications/Toxicity (7)					
Performance Status (8)					
Time to Progression/Treatment Failure					
Survival					

- (1) Infiltrating ductal, lobular (small-cell), medullary, tubular, squamous cell, adenocarcinoma, angiosarcoma
- (2) Positive or negative estrogen receptor
- (3) TNM staging criteria
- (4) Pre- or postmenopausal
- (5) Radical mastectomy, modified radical mastectomy, limited excision (lumpectomy)
- (6) CMF (cyclophosphamide, methotrexate, 5-fluorouracil), CA (cyclophosphamide and doxorubicin), tamoxifen
- (7) NCI common toxicity scale-Hematopoietic (leukopenia, neutropenia, anemia, thrombocytopenia), infectious (fever, localized infection, sepsis), neurological, endocrine (hyper- or hypoglycemia), cardiac (CHF), constitutional (nausea, vomiting, malnutrition, stomatitis, lethargy, malaise)
- (8) Karnofsky

FIG. 66

PATIENT CHARACTERISTICS	RESPONSE				Work Participation
	Clinical	Complete Resource Use	Partial QOL	Overall QALYS	
Demographics					
Age					
Pathology					
Tumor Size					
Histology					
<i>Infiltrating Ductal</i>					
<i>Lobular</i>					
<i>Medullary</i>					
<i>Tubular</i>					
<i>Squamous Cell</i>					
<i>Adenocarcinoma</i>					
<i>Angiosarcoma</i>					
<i>Other</i>					
Estrogen Receptor Status					
<i>Positive</i>					
<i>Negative</i>					
Site of Metastasis					
<i>Nodes</i>					
<i>Lung</i>					
<i>Bone</i>					
<i>Brain</i>					
<i>Liver</i>					
<i>Skin/Soft Tissue</i>					
<i>Adrenal</i>					
<i>Other</i>					
Clinical Status					
Disease Stage					
<i>Stage 0</i>					
<i>Stage I</i>					
<i>Stage IIA</i>					
<i>Stage IIB</i>					
<i>Stage IIIA</i>					
<i>Stage IIIB</i>					
<i>Stage IV</i>					
Menopausal Status					
<i>Premenopause</i>					
<i>Postmenopause</i>					
Prior Treatment Status					
<i>Surgical</i>					
Radical Mastectomy					
Modified Radical Mastectomy					
Limited Excision					
Other					
<i>Chemotherapy</i>					
CMF					
CA					
Tamoxifen					
Other					
<i>Radiotherapy</i>					
Treatment Status					
Complications/Toxicity					
<i>Hematopoietic</i>					
<i>Infectious</i>					
<i>Neurological</i>					
<i>Endocrine</i>					
<i>Cardiac</i>					
<i>Constitutional</i>					
Performance Status					
Time to Progression/Treatment Failure					
Survival					

Fig. 6c